摘要
分化型甲状腺癌是一种罕见的恶性肿瘤,但许多幸存者被终身随访。当前随访的指导方针的基础是通过测量血清中的特定甲状腺肿瘤标记和血清甲状腺球蛋白。大部分病人能够通过这种办法被随访,但是一些甲状腺癌患者在诊断和治疗后,血清中都存在抗甲状腺球蛋白抗体,因而可以开始随访。这些抗体干扰技术在测量甲状腺球蛋白和抗甲状腺球蛋白抗体阳性的病人的免疫学方法中被从现行指导方针中淘汰掉了。近些年的研究表明血清中抗甲状腺球蛋白抗体的浓度可能是一个甲状腺癌复发的替代指标。这最近导致了一个专家意见书的发表,为这些特殊患者提供一个治疗详图。这篇综述总结了支撑这个意见书的一些基础文献。
关键词: 抗甲状腺球蛋白抗体,甲状腺球蛋白,抗体干扰,分化型甲状腺癌,随访
Current Medicinal Chemistry
Title:Thyroglobulin Autoantibodies as Surrogate Biomarkers in the Management of Patients with Differentiated Thyroid Carcinoma
Volume: 21 Issue: 32
Author(s): U. Feldt-Rasmussen, F.A. Verburg, M. Luster, C. Cupini, L. Chiovato, L. Duntas, R. Elisei, H. Rimmele, E. Seregni, J.W.A. Smit, C. Theimer and L. Giovanella
Affiliation:
关键词: 抗甲状腺球蛋白抗体,甲状腺球蛋白,抗体干扰,分化型甲状腺癌,随访
摘要: Differentiated thyroid cancer is a rare malignancy, but leaves numerous survivors for life-long follow-up. The cornerstone in current guidelines for follow-up is by measuring the thyroid specific tumour marker, thyroglobulin in serum. Most patients can be followed by this method, but some thyroid cancer patients have antithyroglobulin antibodies in serum, both at diagnosis and after treatment, where follow-up is commenced. These antibodies interfere technically in the immunological methods for measuring thyroglobulin, and the antithyroglobulin antibody positive patients are thus eliminated from following current guidelines. In recent years studies have indicated that following the concentration of antithyroglobulin antibodies in serum may be a surrogate marker for recurrence of the thyroid carcinoma. This has recently resulted in publication of an expert position paper, providing a flow scheme for these particular patients. The current review summarises the literature which is the basis for the paper.
Export Options
About this article
Cite this article as:
Feldt-Rasmussen U., Verburg F.A., Luster M., Cupini C., Chiovato L., Duntas L., Elisei R., Rimmele H., Seregni E., Smit J.W.A., Theimer C. and Giovanella L., Thyroglobulin Autoantibodies as Surrogate Biomarkers in the Management of Patients with Differentiated Thyroid Carcinoma, Current Medicinal Chemistry 2014; 21 (32) . https://dx.doi.org/10.2174/0929867321666140826120844
DOI https://dx.doi.org/10.2174/0929867321666140826120844 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MicroRNAs (miRNAs) as Biomarker(s) for Prognosis and Diagnosis of Gastrointestinal (GI) Cancers
Current Pharmaceutical Design Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion
Current Drug Targets Role of miRNAs in Muscle Stem Cell Biology: Proliferation, Differentiation and Death
Current Pharmaceutical Design The Biological Effects of Diagnostic Cardiac Imaging
Current Pharmaceutical Design Mediterranean Diet and Dementia of the Alzheimer Type
Current Aging Science Patent Annotations
Recent Patents on Anti-Infective Drug Discovery Clinical Application of Ghrelin
Current Pharmaceutical Design Colony-Stimulating Factor-1 Receptor Inhibitors for the Treatment of Cancer and Inflammatory Disease
Current Topics in Medicinal Chemistry Synthesis and Biological Evaluation of Diaryl Ether Linked DC-81 Conjugates as Potential Antitumor Agents
Anti-Cancer Agents in Medicinal Chemistry Applications of Lipid based Formulation Technologies in the Delivery of Biotechnology-based Therapeutics
Current Pharmaceutical Biotechnology Radionuclide Antibody-Conjugates, a Targeted Therapy Towards Cancer
Current Radiopharmaceuticals Novel Strategies in Drug Discovery of the Calcium-Sensing Receptor Based on Biased Signaling
Current Drug Targets The ALK Gene, An Attractive Target for Inhibitor Development
Current Topics in Medicinal Chemistry Epigenetic Regulation of Epithelial-Mesenchymal Transition by Hypoxia in Cancer: Targets and Therapy
Current Pharmaceutical Design Imaging Methods in Gene Therapy of Cancer
Current Gene Therapy Mechanisms Underlying the Hepatotoxic Effects of Ecstasy
Current Pharmaceutical Biotechnology Vitamin D and Cardiovascular Disease: A Novel Agent for Reducing Cardiovascular Risk?
Current Vascular Pharmacology Cell Cycle Regulatory Protein 5 (Cdk5) is a Novel Downstream Target of ERK in Carboplatin Induced Death of Breast Cancer Cells (Supplementary Data)
Current Cancer Drug Targets Lipid-Based Drug Delivery Systems for Cancer Treatment
Current Drug Targets The RNA Binding Protein HuR: a Promising Drug Target for Anticancer Therapy
Current Cancer Drug Targets